Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Tebipenem Pivoxil Hydrobromide in Healthy Participants
NCT06727136Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tebipenem in complicated urinary tract infection (cUTI) (3 cohorts), sponsored by Spero Therapeutics. Primary endpoints: Maximum Observed Concentration at Day 7, Time to Maximum Observed Concentration at Day 7 and 3 more. Started Nov 2024; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT06727136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727136.